An observational study in Herpes Simplex Infections, Human Papillomavirus and Epstein-Barr Virus Infections, sponsored by The Center for the Biology of Chronic Disease. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-26.
Sponsored by The Center for the Biology of Chronic Disease · Observational
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 1,000 is above the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →This is the only study on the registry with The Center for the Biology of Chronic Disease as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Men and women ages greater than 18 years old
Exclusion Criteria:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
frequency of symptoms
Time frame: one year
duration of symptoms
Time frame: one year
time to first recurrence
Time frame: one year
Plan to share: Undecided
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.